News
Rituximab Improves Survival in CD20+ B-Lineage ALL
- Author:
- Neil Osterweil
Major Finding: In standard-risk patients with B-lineage CD20+ acute lymphoblastic leukemia, the addition of rituximab improved the continuous 5-...
News
No Increased Cancer Risk Seen in Stem Cell, Marrow Donors
- Author:
- Neil Osterweil
Major Finding: The standard incidence ratio for all malignancies among all donors was 0.99.Data Source: Survey based on 55,228 observation-years...
News
Liposomal Cytarabine-Daunorubicin Improves AML Remission Rates
- Author:
- Neil Osterweil
Major Finding: Novel CPX-351 was associated with significantly better overall survival in a subgroup of patients with secondary AML (median, 12.1...
News
Romidepsin Induces Complete Response in Peripheral T-Cell Lymphoma
- Author:
- Neil Osterweil
Major Finding: Romidepsin was associated with a 13% complete response rate in patients with peripheral T-cell lymphoma that had relapsed or was...
News
R-ACVBP Gives Survival Edge Over R-CHOP in Patients With DLBCL
- Author:
- Neil Osterweil
Major Finding: Among patients younger than age 60 who had diffuse large B-cell lymphoma, the 3-year overall survival rates were 92% for those...
News
VRD Plus Lenalidomide Maintenance Yields Good Results in Myeloma
- Author:
- Neil Osterweil
Major Finding: 84% of patients with previously untreated multiple myeloma had a very good partial response or better following induction,...
News
Subcutaneous Bortezomib in Myeloma Matches IV For Efficacy, Has Better Safety Profile
- Author:
- Neil Osterweil
News
Rituximab Reduces Chronic GVHD After Allogeneic Stem Cell Transplant
- Author:
- Neil Osterweil
Major Finding: Rituximab prophylaxis reduced the incidence of chronic GVHD following allogeneic stem cell transplant by at least 50%.Data Source:...
News
Bortezomib-Based Regimens Help Older Patients With Multiple Myeloma
- Author:
- Neil Osterweil
Major Finding: Very good partial response rates ranged from 39% to 47% after maintenance therapy in a comparison of three bortezomib-containing...
News
Ara-C Prolongs Time to Treatment Failure in Mantle Cell Lymphoma
- Author:
- Neil Osterweil
Major Finding: A conditioning regimen of R-CHOP alternating with R-DHAP and high dose cytarabine followed by stem-cell transplant improved time to...
News
BEACOPP Plus ABVD Called 'New Standard' for Hodgkin's Lymphoma
- Author:
- Neil Osterweil
Major Finding: Combining two cycles of BEACOPP with two of ABVD significantly improves time to treatment failure (but not overall survival) in...
News
Imatinib Plus Bone Marrow Transplant Boost Survival in Ph+ ALL
- Author:
- Neil Osterweil
Major Finding: The 3-year overall survival of Philadelphia chromosome–positive ALL improved from 25%, before imatinib was introduced, to 43% after...
News
Scoring System Predicts Recurrent VTE Risk in Cancer Patients
- Author:
- Neil Osterweil
Major Finding: Predictors for risk of recurrent venous thromboembolism (VTE) in cancer patients are lung cancer, female gender, and a prior VTE....
News
Study Shows Rivaroxaban Valid for VTE Prophylaxis
- Author:
- Neil Osterweil
Major Finding: Venous thromboembolism recurred in 2.1% of patients randomized to rivaroxaban and in 3.0% of patients randomized to enoxaparin...
News
Study Shows Rivaroxaban Valid for VTE Prophylaxis
- Author:
- Neil Osterweil
Major Finding: Venous thromboembolism recurred in 2.1% of patients randomized to rivaroxaban and in 3.0% of patients randomized to enoxaparin...